Arcalyst approved for CAPS

Regeneron has received FDA approval for Arcalyst (rilonacept injection) for the treatment of cryopyrin-associated periodic syndromes (CAPS) in patients ≥12 years of age. Arcalyst, an interleukin-1 (IL-1) inhibitor, is expected to be available in April 2008.

For more information call (877) REGN-777 or visit www.arcalyst.com.